Back to top
more

ImmunoGen, Inc. (IMGN)

(Delayed Data from NSDQ)

$2.33 USD

2.33
1,077,203

+0.02 (0.87%)

Updated Jul 19, 2019 03:58 PM ET

Add to portfolio

2-Buy   2      

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.80%
17.93%
9.58%
5.18%
2.03%
10.63%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | A Growth | B Momentum | C VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Balance Sheet

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for IMGN

   

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

Fiscal Year End for ImmunoGen, Inc. falls in the month of December.

All items in Millions except Per Share data.

12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Assets          
Cash & Equivalents 262 267 160 245 278
Receivables 12 5 9 2 6
Notes Receivable 0 0 0 0 0
Inventories 0 1 2 1 3
Other Current Assets 5 3 5 7 5
Total Current Assets 279 276 176 255 292
Net Property & Equipment 13 15 19 23 16
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 6 4
Intangibles 0 0 0 0 0
Deposits & Other Assets 4 4 3 3 1
Total Assets 295 295 199 287 314
Liabilities & Shareholders Equity 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Notes Payable 0 0 0 0 0
Accounts Payable 11 9 8 12 8
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 32 27 18 20 19
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 27 20 30 29 9
Total Current Liabilities 71 56 56 61 36
Mortgages 0 0 0 0 0
Deferred Taxes/Income 85 99 25 26 47
Convertible Debt 2 2 97 100 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 127 156 174 182 196
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 284 313 352 369 279
Shareholders Equity 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 1,193 1,009 779 771 743
Retained Earnings -1,183 -1,029 -933 -854 -709
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 11 -18 -153 -82 35
Total Liabilities & Shareholder's Equity 295 295 199 287 314
Total Common Equity 11 -18 -153 -82 35
Shares Outstanding 149.00 132.20 87.30 86.90 85.90
Book Value Per Share 0.07 -0.14 -1.75 -0.95 0.41

Fiscal Year End for ImmunoGen, Inc. falls in the month of December.

All items in Millions except Per Share data.

6/30/2019 3/31/2019 12/31/2018 9/30/2018 6/30/2018
Assets          
Cash & Equivalents NA 270 262 303 345
Receivables NA 13 12 11 8
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 2 2
Other Current Assets NA 7 5 7 10
Total Current Assets NA 290 279 323 365
Net Property & Equipment NA 14 13 13 12
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 20 4 4 4
Total Assets NA 324 295 340 381
Liabilities & Shareholders Equity 6/30/2019 3/31/2019 12/31/2018 9/30/2018 6/30/2018
Notes Payable NA 0 0 0 0
Accounts Payable NA 9 11 10 13
Current Portion Long-Term Debt NA 3 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 25 32 34 26
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 25 27 26 24
Total Current Liabilities NA 61 71 70 63
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 146 85 85 86
Convertible Debt NA 2 2 2 2
Long-Term Debt NA 24 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 127 135 141
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 352 284 293 292
Shareholders Equity 6/30/2019 3/31/2019 12/31/2018 9/30/2018 6/30/2018
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 1 1 1 1
Capital Surplus NA 1,198 1,193 1,187 1,182
Retained Earnings NA -1,227 -1,183 -1,142 -1,095
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA -28 11 47 89
Total Liabilities & Shareholder's Equity NA 324 295 340 381
Total Common Equity 0 -28 11 47 89
Shares Outstanding 149.50 149.50 149.00 149.00 133.00
Book Value Per Share 0.00 -0.18 0.07 0.31 0.67